A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. Other presentations looked at predictions about eradication of HIV/HCV coinfection in France and rising incidence of HCV infection among HIV-positive gay men in San Diego.
The number of annual new HIV infections in the U.S. fell by 18% overall since 2008, offering evidence that prevention and treatment efforts are having an impact, according to data from the Centers for Disease Control and Prevention (CDC) released to coincidence with presentations at the 2017 Conference on Retroviruses and Opportunistic Infections this week in Seattle. A closer look at the data, however, shows some notable differences across demographic groups and geographic regions.
Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.